#USA #New York #Immunic #Aberdeen Investments #IMUX

Immunic, Inc. Secures $5.1 Million in Direct Offering

On April 9, 2025, Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company focused on developing innovative therapies for chronic inflammatory and autoimmune diseases, announced the pricing for its latest direct offering. This offering involves 5,666,667 shares of common stock priced at $0.90 per share, aiming to raise approximately $5.1 million before deducting commissions and offering expenses. This initiative is spearheaded by Aberdeen Investments, a notable player in the investment sector.

The funds generated from this offering are earmarked primarily for enhancing Immunic's clinical trials and operational activities, reinforcing its commitment to advancing its product pipeline. Notably, the offering is scheduled to close on or around April 10, 2025, pending the satisfaction of customary closing conditions. Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for this offering, ensuring strategic support throughout the process.

Immunic's projects largely revolve around small molecule therapies aimed at treating a spectrum of difficult-to-manage chronic inflammatory and autoimmune conditions. Their flagship product, vidofludimus calcium (IMU-838), is currently in advanced stages of clinical trials, specifically Phase 3 and Phase 2, addressing challenges associated with relapsing and progressive multiple sclerosis. Early results have showcased promising therapeutic effects among patients suffering from various forms of multiple sclerosis, as well as conditions like moderate-to-severe ulcerative colitis.

Vidofludimus calcium is distinguished by its dual action: it exerts neuroprotective benefits as a first-in-class nuclear receptor related 1 (Nurr1) activator while also possessing anti-inflammatory and anti-viral properties through the selective inhibition of dihydroorotate dehydrogenase (DHODH). This unique combination positions it as a compelling candidate in the competitive pharmaceutical landscape.

Additionally, Immunic is advancing its second candidate, IMU-856, which targets Sirtuin 6 (SIRT6) to rejuvenate intestinal barrier function, showing potential applicability in various gastrointestinal disorders, such as celiac disease and inflammatory bowel disease. The company's development pipeline also includes IMU-381, currently in preclinical development, aimed at addressing specific gastrointestinal needs.

In accordance with regulatory requirements, this offering follows a shelf registration statement filed with the Securities and Exchange Commission (SEC), which simplifies the process of capital raising through registered securities. The company asserts that this strategic move will bolster its capacity to drive its innovative pipeline forward amidst ongoing clinical challenges and ensure sustained growth.

As a reflection of its proactive stance, Immunic emphasizes its dedication to transparency and regulatory compliance, reinforcing its reputation among stakeholders. Investors looking for detailed information regarding this offering can access materials available on the SEC's website, or contact Titan Partners Group directly.

In summary, Immunic, Inc.'s recent $5.1 million registered direct offering stands as a testament to its ambitious growth trajectory. By securing this funding, the company is not only poised to enhance its clinical trials but also reaffirm its pivotal role in the biotechnology sector dedicated to combatting chronic inflammatory and autoimmune diseases. Investors and industry watchers are keen to see how this financial boost will empower Immunic to meet its developmental goals, potentially leading to groundbreaking advancements in treatment options for affected patients.